A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers

Author:

Smith Patrick F.1ORCID,Krishnarajah Janakan2,Nunn Philip A.3,Hill Ron J.3,Karr Dane3,Tam D.3,Masjedizadeh Mohammad3,Funk Jens O.3,Gourlay Steve G.3

Affiliation:

1. d3 Medicine; A Certara Company; Parsippany New Jersey USA

2. Linear Clinical Research; Perth Australia

3. Principia Biopharma; Melbourne Australia

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference17 articles.

1. The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy;Crofford;Expert Rev Clin Immunol,2016

2. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis;Di Paolo;Nat Chem Biol,2011

3. Bruton's tyrosine kinase-an integral protein of B cell development that also has an essential role in the innate immune system;Lopez-Herrera;J Leukoc Biol,2014

4. The many faces of Bruton's tyrosine kinase;McAtee;Nat Biotechnol,2012

5. Bruton's tyrosine kinase as a drug discovery target;Pan;Drug News Perspect,2008

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3